AstraZeneca Opens Global R&D Centre in Cambridge’s Kendall Square

AstraZeneca on 5 October 2026 announced the opening of its newest global strategic research and development centre in Kendall Square, Cambridge, Massachusetts, a facility the company said places its scientists at the heart of one of the world’s most innovative life sciences ecosystems. The new site builds on the company’s existing presence in Cambridge and Boston and is backed by an investment of more than US$1 billion in Massachusetts, part of AstraZeneca’s broader $50 billion investment plan for the United States.

The company said the Massachusetts investment will directly expand its workforce in the state by over 50 per cent in the coming years and contribute billions in additional economic value and jobs across the Commonwealth. AstraZeneca described the opening of the laboratories as a significant milestone in its more than 75-year history in Massachusetts.

Facility Specifications and Research Scope

The AstraZeneca R&D Center Kendall Square occupies a 570,000-square-foot, 18-story site at 290 Binney Street. The company said the building is designed to enhance collaboration and was built with the highest standards of sustainable design. It said the centre includes ten floors of interconnecting laboratories designed to allow a seamless flow of science, enabled by technologies that integrate robotics, continuous automation and agentic AI.

Together with AstraZeneca’s site for genomic medicine at 100 Binney Street, the new centre will be home to nearly 2,000 researchers and scientists, according to the company. AstraZeneca (AZN ) said they will work to accelerate the company’s oncology, cell therapy, chronic disease and rare disease pipeline, and that leading experts at the site will deliver novel treatments from that pipeline for people living with diseases including COPD, obesity and metabolic disease, breast cancer and rare diseases. The company said the centre will also focus on the next wave of future innovation in areas such as cell therapy and biologics to fuel its growth beyond 2030.

Pascal Soriot, Chief Executive Officer of AstraZeneca, said: “Kendall Square is a leading innovation ecosystem, and it is one of the key locations where AstraZeneca will discover the next generation of scientific breakthroughs. Our new R&D centre not only reflects AstraZeneca’s long-term commitment to Massachusetts but also our belief in delivering US-led innovation to patients around the world.”

Maura Healey, Governor of Massachusetts, said: “AstraZeneca’s more than $1 billion investment is a major vote of confidence in Massachusetts and the extraordinary talent we have here.” Healey added that Massachusetts is a global leader in life sciences and that the state will keep competing for the investments, jobs and breakthroughs that will define the next generation of medicine.

AstraZeneca said the state’s concentration of scientific talent, leading academic institutions, healthcare systems and industry partners makes Massachusetts a critical hub for the company. It said it is committed to creating lasting scientific and community value across the ecosystem through academic research partnerships, investments in STEM education, workforce development and local organizations that support the future biomedical research workforce.

US Footprint and the 2025 Investment Plan

The Kendall Square site adds to AstraZeneca’s existing R&D presence in more than 40 countries, including its other US-based global strategic research centre in Gaithersburg, Maryland. In the US, the new centre joins a coast-to-coast footprint of 24 R&D, manufacturing, commercial and corporate sites. The company said its US workforce exceeds 25,000 people and supports nearly 100,000 jobs overall across the country.

The centre is among the components of the $50 billion of investment in the United States by 2030 that AstraZeneca announced on 21 July 2025. That plan listed a state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts alongside an expansion of the company’s R&D facility in Gaithersburg, Maryland; next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California; continuous manufacturing expansion in Mount Vernon, Indiana; specialty manufacturing expansion in Coppell, Texas; new sites to supply clinical trials; and growing research and development investment in novel medicines.

The cornerstone of the July 2025 announcement was a proposed multi-billion dollar US manufacturing facility, planned for the Commonwealth of Virginia, that AstraZeneca said would produce drug substances for its weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The company said the facility, which would be its largest single manufacturing investment in the world, will produce small molecules, peptides and oligonucleotides and will leverage AI, automation and data analytics. It said that capital investment is in addition to $3.5 billion announced in November 2024.

AstraZeneca said in July 2025 that the investments collectively would help deliver its ambition of reaching $80 billion in Total Revenue by 2030, of which it expects 50 per cent would be generated in the US. The company said at the time that the plan was expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country.

At the time of the July 2025 announcement, AstraZeneca stated that the US was its largest market and home to 19 R&D, manufacturing and commercial sites, with more than 18,000 employees and 92,000 supported jobs overall, and that the US represented 42 per cent of its Total Revenue. The company also stated that in 2024 it contributed $5 billion directly to the US economy and created approximately $20 billion worth of overall value for the American economy, and that it held an ambition to launch 20 new medicines by the end of the decade.